Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED

Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022

April 21, 2022

From Ambrx, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022 ↗

April 07, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022 ↗

February 28, 2022

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...

Via Benzinga

Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA

February 15, 2022

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee

February 07, 2022

From Ambrx, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

January 26, 2022

During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company...

Via Benzinga

Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial ↗

December 09, 2021

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-...

Via Benzinga

55 Biggest Movers From Yesterday ↗

December 22, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low ↗

December 09, 2021

Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S...

Via Benzinga

Topics Stocks

Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium

December 09, 2021

From Ambrx Biopharma Inc.

Via Business Wire

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

November 19, 2021

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer

November 04, 2021

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference

November 01, 2021

From Ambrx, Inc.

Via Business Wire

Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update

October 28, 2021

From Ambrx, Inc.

Via Business Wire

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products ↗

October 10, 2021

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed...

Via Talk Markets

Topics Initial Public Offering

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment ↗

October 05, 2021

Photo by Dimitri Karastelev on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, strives to discover new treatments for mental and neurological...

Via Benzinga

Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO

October 04, 2021

From Ambrx, Inc.

Via Business Wire

Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

September 09, 2021

From Ambrx, Inc.

Via Business Wire

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

August 03, 2021

From Ambrx

Via Business Wire

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

These 3 New Biotechs Have Differentiated Platforms, Technology: BofA ↗

July 13, 2021

Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ:

Via Benzinga

Topics Initial Public Offering

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗

July 11, 2021

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

54 Biggest Movers From Yesterday ↗

July 16, 2021

Gainers Sight Sciences, Inc. (NASDAQ: SGHT) shares jumped 39.6% to settle at $33.50 on Thursday as the company priced its IPO at $24 per share. Cinedigm Corp. (NASDAQ: CIDM)...

Via Benzinga

Topics Initial Public Offering

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 ↗

July 13, 2021

Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.